search
Back to results

Enhanced External Counterpulsation in Patients With Fontan Circulation

Primary Purpose

Single-ventricle, Congenital Heart Disease

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
EECP
Sponsored by
Boston Children's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Single-ventricle focused on measuring Fontan

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Individuals with Fontan physiology being seen in the Boston Children's Hospital cardiology clinic for outpatient care.

Exclusion Criteria:

  • Current pregnancy
  • Decompensated heart failure/pulmonary edema
  • Severe aortic insufficiency
  • Active tachyarrhythmias
  • Frequent atrial or ventricular ectopy
  • Symptomatic peripheral vascular disease
  • Thrombophlebitis or history of deep vein thrombosis or stasis ulcer
  • Aortic aneurysm
  • Uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure>110 mmHg)
  • Systolic blood pressure <90 mmHg
  • Active femoral site bleeding or hematoma

Sites / Locations

  • Boston Children's Hospital

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Enhanced External Counterpulsation (EECP)

Arm Description

1 hour of treatment with EECP

Outcomes

Primary Outcome Measures

Change in cardiac output
Measurement of cardiac output (pulmonary blood flow) in L/min using inert gas rebreathing method (Innocor CO device)
Total number and type of adverse events during EECP treatment
Adverse events will be collected by an investigator and documented using CTCAE criteria
Total number and type of adverse events immediately following EECP treatment
Adverse events will be collected by an investigator and documented using CTCAE criteria

Secondary Outcome Measures

Change in ventricular strain analysis
Global mid-ventricle circumferential strain (%) and global longitudinal strain (%) calculated from speckle-tracking echocardiography
Change in qualitative ventricular systolic function
Qualitative assessment of systolic function of dominant ventricle on 2-dimensional echocardiography, categorized as normal, low normal to mildly depressed, mildly depressed, mildly to moderately depressed, moderately depressed, moderately to severely depressed, severely depressed, or unable to determine.
plasma endothelin (ET-1)
This will measure endothelial function
Total nitrate/nitrite (NOx) levels
This will measure endothelial function

Full Information

First Posted
June 1, 2021
Last Updated
June 10, 2023
Sponsor
Boston Children's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04956952
Brief Title
Enhanced External Counterpulsation in Patients With Fontan Circulation
Official Title
Enhanced External Counterpulsation in Patients With Fontan Circulation
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
March 31, 2022 (Actual)
Primary Completion Date
May 17, 2023 (Actual)
Study Completion Date
May 17, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Boston Children's Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the proposed study is to determine the safety of enhanced external counterpulsation (EECP), a system for compressing the blood vessels in the legs in synchrony with an individual's cardiac rhythm, in clinically well, adult Fontan patients, to document the acute hemodynamic and myocardial effects of EECP on the Fontan circulation, and to demonstrate acute changes in endothelial function after one hour of the procedure.
Detailed Description
The investigators plan to study the effects of enhanced external counterpulsation (EECP), on patients who have had Fontan surgery for treatment of complex congenital heart disease. Eligible patient volunteers will undergo a series of biophysical measurements at rest including echocardiographic assessment of ventricular function, pulmonary blood flow/cardiac output measurement using an inert gas rebreathing method (Innocor), and measurements of biomarkers of endothelial function (ET-1, NOx). Patients will then undergo 1 hour of treatment with EECP, during which additional echocardiographic assessment of ventricular function and pulmonary blood flow/cardiac output measurements will be performed at multiple levels of leg compression. Subjects will be assessed periodically for adverse effects and discomfort during the EECP treatment. At the completion of treatment, patients will be allowed 30 minutes to rest before undergoing one more echocardiographic assessment of ventricular function, pulmonary blood flow/cardiac output measurement, and measurements of biomarkers of endothelial function (ET-1, NOx). Measurements made during and after treatment will be compared to baseline measurements.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Single-ventricle, Congenital Heart Disease
Keywords
Fontan

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
23 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Enhanced External Counterpulsation (EECP)
Arm Type
Other
Arm Description
1 hour of treatment with EECP
Intervention Type
Device
Intervention Name(s)
EECP
Intervention Description
1 hour of treatment with EECP
Primary Outcome Measure Information:
Title
Change in cardiac output
Description
Measurement of cardiac output (pulmonary blood flow) in L/min using inert gas rebreathing method (Innocor CO device)
Time Frame
Immediately prior to starting EECP treatment, during each 20-minute phase of EECP treatment, and 30 minutes after EECP treatment
Title
Total number and type of adverse events during EECP treatment
Description
Adverse events will be collected by an investigator and documented using CTCAE criteria
Time Frame
During EECP treatment (duration 60 minutes)
Title
Total number and type of adverse events immediately following EECP treatment
Description
Adverse events will be collected by an investigator and documented using CTCAE criteria
Time Frame
From completion of EECP treatment until patient discharge (30 to 60 minutes)
Secondary Outcome Measure Information:
Title
Change in ventricular strain analysis
Description
Global mid-ventricle circumferential strain (%) and global longitudinal strain (%) calculated from speckle-tracking echocardiography
Time Frame
Immediately prior to starting EECP treatment, during each 20-minute phase of EECP treatment, and 30 minutes after EECP treatment
Title
Change in qualitative ventricular systolic function
Description
Qualitative assessment of systolic function of dominant ventricle on 2-dimensional echocardiography, categorized as normal, low normal to mildly depressed, mildly depressed, mildly to moderately depressed, moderately depressed, moderately to severely depressed, severely depressed, or unable to determine.
Time Frame
Immediately prior to starting EECP treatment, during each 20-minute phase of EECP treatment, and 30 minutes after EECP treatment
Title
plasma endothelin (ET-1)
Description
This will measure endothelial function
Time Frame
pre and 30 minutes post EECP treatment
Title
Total nitrate/nitrite (NOx) levels
Description
This will measure endothelial function
Time Frame
pre and 30 minutes post EECP treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Individuals with Fontan physiology being seen in the Boston Children's Hospital cardiology clinic for outpatient care. Exclusion Criteria: Current pregnancy Decompensated heart failure/pulmonary edema Severe aortic insufficiency Active tachyarrhythmias Frequent atrial or ventricular ectopy Symptomatic peripheral vascular disease Thrombophlebitis or history of deep vein thrombosis or stasis ulcer Aortic aneurysm Uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure>110 mmHg) Systolic blood pressure <90 mmHg Active femoral site bleeding or hematoma
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fred Wu, MD
Organizational Affiliation
Attending Cardiologist
Official's Role
Principal Investigator
Facility Information:
Facility Name
Boston Children's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Enhanced External Counterpulsation in Patients With Fontan Circulation

We'll reach out to this number within 24 hrs